CAR-T cost effectiveness study | Dana-Farber Cancer Institute

Описание к видео CAR-T cost effectiveness study | Dana-Farber Cancer Institute

A new study in Annals of Internal Medicine, led by Amar Kelkar, MD, MPH, Dana-Farber, found CAR-T is not cost-effective as second-line therapy for diffuse large B-cell lymphoma at current prices.
Read more: http://ms.spr.ly/6052ipmke

Комментарии

Информация по комментариям в разработке